KTP 001
Alternative Names: KTP-001; Recombinant human matrix metalloproteinase - KM Biologics/TeijinLatest Information Update: 21 Jun 2021
At a glance
- Originator University of Yamanashi; Yokohama City Minato Red Cross Hospital
- Developer KM Biologics; Teijin Pharma
- Class Matrix metalloproteinases; Recombinant proteins
- Mechanism of Action Matrix metalloproteinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Intervertebral disc displacement
Most Recent Events
- 18 Jun 2021 Discontinued - Phase-I/II for Intervertebral disc displacement in USA (Intraspinal) (Teijin Pharma pipeline, June 2021)
- 31 Jul 2019 KTP 001 is still in phase I/II trials for Intervertebral disc displacement in the US
- 16 Oct 2018 Teijin Pharma completes a phase I/II trial in Intervertebral disc displacement in USA (NCT01978912)